论文部分内容阅读
目的研究分析化疗间期序贯应用厄洛替尼治疗晚期非小细胞肺癌的临床疗效观察。方法 77例晚期非小细胞肺癌患者,其中41例初治患者采用吉西他滨联合铂类进行化疗治疗为研究组,36例复治患者则采用培美曲塞或者多西他赛进行治疗,在化疗间期进行序贯给予厄洛替尼进行治疗为对照组,观察两组患者的客观缓解情况以及不良反应。结果研究组患者临床有效率为26.8%,对照组为22.2%,两组临床有效率对比差异无统计学意义(P>0.05);研究组患者临床控制率为80.5%,对照组为61.1%,研究组临床控制率优于对照组(P<0.05)。两组患者化疗期间主要药物反应为恶心呕吐、皮疹、食欲减退以及腹泻等,血液毒性反应主要为血小板减少和中性粒细胞减少,两组患者临床用药反应差异无统计学意义(P>0.05)。结论化疗间期序贯应用厄洛替尼治疗晚期非小细胞肺癌效果较好,且耐受性较好。
Objective To study the clinical efficacy of sequential chemotherapy with erlotinib in the treatment of advanced non-small cell lung cancer. Methods A total of 77 patients with advanced non-small cell lung cancer were enrolled. Among them, 41 patients were treated with gemcitabine combined with platinum for chemotherapy and 36 patients treated with pemetrexed or docetaxel. Erlotinib given sequential treatment for the control group, observe the two groups of patients objective response and adverse reactions. Results The clinical effective rate was 26.8% in the study group and 22.2% in the control group. There was no significant difference in clinical efficacy between the two groups (P> 0.05). The clinical control rate was 80.5% in the study group and 61.1% in the control group, The clinical control rate of the study group was better than that of the control group (P <0.05). The main drug reactions during the chemotherapy in the two groups were nausea, vomiting, rash, loss of appetite and diarrhea. The main hematologic toxicities were thrombocytopenia and neutropenia. There was no significant difference in clinical medication response between the two groups (P> 0.05) . Conclusion The sequential chemotherapy with erlotinib in the treatment of advanced non-small cell lung cancer is better and more tolerable.